Closing the diagnostic gap in transthyretin cardiac amyloidosis: red flags, modern imaging, and emerging therapies. (PubMed, Front Cardiovasc Med) - Oct 15, 2026 - "Third, treatment options now extend beyond tafamidis to acoramidis and vutrisiran, with amyloid-depleting antibodies under active investigation. We propose a pragmatic, resource-stratified diagnostic framework for targeted case-finding rather than population-level screening."
Journal • Review • Amyloidosis • Cardiac Amyloidosis • Cardiomyopathy • Cardiovascular • Heart Failure • Musculoskeletal Diseases • Orthopedics
|
|
Peng Li; Xueqian Wang; Zhengjun Yi
|